Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GMED NYSE:HAE NYSE:HRC NYSE:INSP NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMEDGlobus Medical$58.18-1.0%$57.82$51.79▼$94.93$7.93B1.16927,079 shs1.24 million shsHAEHaemonetics$51.39-1.6%$63.30$50.68▼$94.99$2.51B0.39886,584 shs1.34 million shsHRCHill-Rom$155.96$155.74$93.34▼$156.22$10.30B0.55656,912 shsN/AINSPInspire Medical Systems$80.90+1.1%$103.93$73.92▼$218.52$2.37B1.15976,843 shs995,650 shsTNDMTandem Diabetes Care$12.09-1.5%$13.49$9.98▼$47.60$829.08M1.451.77 million shs1.40 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMEDGlobus Medical0.00%-3.00%-3.13%-0.31%-15.80%HAEHaemonetics0.00%-3.89%-3.01%-25.37%-31.36%HRCHill-Rom0.00%0.00%0.00%0.00%0.00%INSPInspire Medical Systems0.00%-7.08%-8.43%-38.09%-60.65%TNDMTandem Diabetes Care0.00%-2.46%+13.40%-38.77%-72.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMEDGlobus Medical$58.18-1.0%$57.82$51.79▼$94.93$7.93B1.16927,079 shs1.24 million shsHAEHaemonetics$51.39-1.6%$63.30$50.68▼$94.99$2.51B0.39886,584 shs1.34 million shsHRCHill-Rom$155.96$155.74$93.34▼$156.22$10.30B0.55656,912 shsN/AINSPInspire Medical Systems$80.90+1.1%$103.93$73.92▼$218.52$2.37B1.15976,843 shs995,650 shsTNDMTandem Diabetes Care$12.09-1.5%$13.49$9.98▼$47.60$829.08M1.451.77 million shs1.40 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMEDGlobus Medical0.00%-3.00%-3.13%-0.31%-15.80%HAEHaemonetics0.00%-3.89%-3.01%-25.37%-31.36%HRCHill-Rom0.00%0.00%0.00%0.00%0.00%INSPInspire Medical Systems0.00%-7.08%-8.43%-38.09%-60.65%TNDMTandem Diabetes Care0.00%-2.46%+13.40%-38.77%-72.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMEDGlobus Medical 2.62Moderate Buy$87.6450.64% UpsideHAEHaemonetics 2.80Moderate Buy$78.7853.29% UpsideHRCHill-Rom 0.00N/AN/AN/AINSPInspire Medical Systems 2.57Moderate Buy$164.50103.34% UpsideTNDMTandem Diabetes Care 2.31Hold$22.4485.59% UpsideCurrent Analyst Ratings BreakdownLatest HRC, INSP, HAE, GMED, and TNDM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025TNDMTandem Diabetes CareOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$44.00 ➝ $22.009/2/2025INSPInspire Medical SystemsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$150.008/21/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$10.35 ➝ $11.008/15/2025INSPInspire Medical SystemsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Perform$116.00 ➝ $97.008/11/2025HAEHaemoneticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$105.00 ➝ $78.008/11/2025TNDMTandem Diabetes CareLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $12.008/8/2025GMEDGlobus MedicalWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$76.00 ➝ $66.008/8/2025HAEHaemoneticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$85.00 ➝ $62.008/8/2025HAEHaemoneticsMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$90.00 ➝ $70.008/8/2025HAEHaemoneticsBarrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$95.00 ➝ $86.008/8/2025TNDMTandem Diabetes CareBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$53.00 ➝ $51.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMEDGlobus Medical$2.52B3.12$6.60 per share8.82$30.40 per share1.91HAEHaemonetics$1.36B1.82$7.10 per share7.24$16.34 per share3.15HRCHill-Rom$3.02B3.41$9.29 per share16.79$28.56 per share5.46INSPInspire Medical Systems$802.80M2.98$1.73 per share46.85$23.01 per share3.52TNDMTandem Diabetes Care$940.20M0.87N/AN/A$4.01 per share3.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMEDGlobus Medical$102.98M$2.6022.3814.441.6113.58%10.65%8.86%11/4/2025 (Estimated)HAEHaemonetics$167.68M$3.2715.7210.200.9612.14%26.64%9.32%11/6/2025 (Estimated)HRCHill-Rom$248.50M$3.7241.9221.72N/A8.23%23.07%8.96%N/AINSPInspire Medical Systems$53.51M$1.7346.7625.122.506.17%10.38%8.93%11/3/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%11/5/2025 (Estimated)Latest HRC, INSP, HAE, GMED, and TNDM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025GMEDGlobus Medical$0.76$0.86+$0.10$1.50$738.91 million$745.34 million8/7/2025Q1 2026HAEHaemonetics$1.01$1.10+$0.09$0.70$305.12 million$321.39 million8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million8/4/2025Q2 2025INSPInspire Medical Systems$0.22$0.45+$0.23-$0.12$214.50 million$217.09 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMEDGlobus MedicalN/AN/AN/AN/AN/AHAEHaemoneticsN/AN/AN/AN/AN/AHRCHill-Rom$0.960.62%N/A25.81%N/AINSPInspire Medical SystemsN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMEDGlobus MedicalN/A4.072.26HAEHaemonetics1.041.721.04HRCHill-Rom0.971.381.05INSPInspire Medical SystemsN/A6.144.84TNDMTandem Diabetes Care2.322.441.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMEDGlobus Medical95.16%HAEHaemonetics99.67%HRCHill-Rom76.45%INSPInspire Medical Systems94.91%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipGMEDGlobus Medical18.54%HAEHaemonetics1.84%HRCHill-Rom0.69%INSPInspire Medical Systems2.30%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMEDGlobus Medical5,300135.06 million110.02 millionOptionableHAEHaemonetics3,02348.18 million47.29 millionOptionableHRCHill-Rom10,00066.05 million65.59 millionOptionableINSPInspire Medical Systems1,24629.57 million28.89 millionOptionableTNDMTandem Diabetes Care2,65067.57 million66.29 millionOptionableHRC, INSP, HAE, GMED, and TNDM HeadlinesRecent News About These CompaniesJim Cramer Calls Tandem Diabetes “Speculative Stock for Younger People”September 13 at 10:31 AM | insidermonkey.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM),September 12 at 11:42 PM | bakersfield.comBTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 12 at 6:46 PM | globenewswire.comAnalysts Set Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Target Price at $22.47September 11, 2025 | americanbankingnews.comTandem Diabetes Care: Strategic Initiatives and Market Challenges Justify Hold RatingSeptember 10, 2025 | tipranks.comRosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDMSeptember 10, 2025 | tmcnet.comRosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation – TNDMSeptember 10, 2025 | businesswire.comTandem Diabetes Care, Inc. (TNDM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comTandem Diabetes Care (NASDAQ:TNDM) Now Covered by Analysts at OppenheimerSeptember 10, 2025 | marketbeat.comFred Alger Management LLC Sells 489,117 Shares of Tandem Diabetes Care, Inc. $TNDMSeptember 10, 2025 | marketbeat.comOppenheimer Begins Coverage on Tandem Diabetes Care (NASDAQ:TNDM)September 10, 2025 | americanbankingnews.comBeyond The Numbers: 12 Analysts Discuss Tandem Diabetes Care StockSeptember 9, 2025 | benzinga.comShort Interest in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Decreases By 34.1%September 9, 2025 | marketbeat.comSessa Capital IM L.P. Acquires Shares of 4,466,307 Tandem Diabetes Care, Inc. $TNDMSeptember 9, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by BrokeragesSeptember 9, 2025 | marketbeat.comPark West Asset Management LLC Has $21.52 Million Stake in Tandem Diabetes Care, Inc. $TNDMSeptember 8, 2025 | marketbeat.comTandem Diabetes Care, Inc. $TNDM Shares Sold by Jacobs Levy Equity Management Inc.September 8, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Short Interest Down 34.1% in AugustSeptember 8, 2025 | americanbankingnews.comTandem Diabetes Care, Inc. $TNDM Stock Holdings Lifted by Raymond James Financial Inc.September 8, 2025 | marketbeat.com252,600 Shares in Tandem Diabetes Care, Inc. $TNDM Acquired by Edmond DE Rothschild Holding S.A.September 7, 2025 | marketbeat.comTandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android PhonesSeptember 6, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRC, INSP, HAE, GMED, and TNDM Company DescriptionsGlobus Medical NYSE:GMED$58.18 -0.57 (-0.96%) Closing price 03:59 PM EasternExtended Trading$57.82 -0.36 (-0.62%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Haemonetics NYSE:HAE$51.39 -0.81 (-1.55%) Closing price 03:59 PM EasternExtended Trading$51.70 +0.31 (+0.61%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Hill-Rom NYSE:HRCHill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.Inspire Medical Systems NYSE:INSP$80.90 +0.85 (+1.06%) Closing price 03:59 PM EasternExtended Trading$80.06 -0.84 (-1.04%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Tandem Diabetes Care NASDAQ:TNDM$12.09 -0.18 (-1.47%) Closing price 04:00 PM EasternExtended Trading$12.09 0.00 (0.00%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
